← GLP-1 receptor agonists × kidney outcomes

TrialThe New England journal of medicine2017

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Johannes F E Mann et al.PubMed ↗Publisher ↗

A later paper about NCT01179048. The trial’s primary report, PMID 27295427, speaks for it on the map; the numbers here are shown and do not vote.

Liraglutidelooks good hereLower new onset of persistent macroalbuminuria, lower renal outcome.Randomised, large.

What the trial testedrandomised · 9,340 people · 2017

Randomised vs placebo

Lowered new onset of persistent macroalbuminuria

Doesn’t vote: a later paper about the trial

−26%−40% to −9%

liraglutide vs placebo

Bigger than 6 in 10 on the map

As reported

HR 0.74, 95% CI 0.60–0.91

Not counted

Lowered renal outcome

−22%−33% to −8%

liraglutide vs placebo

6 in 100 instead of 7

Bigger than 5 in 10 on the map

As reported

HR 0.78, 95% CI 0.67–0.92

Who was studied, and how

9,341people in the A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events trial, from 2010

9,340of them with kidney disease, in this paper

The trial randomly assignedassigned by chance

liraglutide

placebo

Lowered new onset of persistent macroalbuminuria−26%

Lowered renal outcome−22%

randomised

the abstract, start to end

… patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], …

… (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; …

← favours treatmentfavours comparator →

could be chance

Renal outcomeliraglutide vs placebo

HR 0.780.67–0.92

New onset of persistent macroalbuminurialiraglutide vs placebo

HR 0.740.60–0.91

GLP-1 receptor agonistsKidney outcomes

1 / 4

527 papers cite itlatest 60 shown

2017

…

2023

2024

2025

2026

this paperpooled ittrialcites it

4 trials

NCT01179048phase 39,341 enrolled2010a later paper about it NCT04529278phase 218 enrolled2021 NCT06894784phase 336 enrolled2025 NCT04231838576 enrolled2021